Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats

European Journal of Pharmaceutical Sciences

Volumn 44, Issue 1-2, 2011, Pages 27-31

  Neerati, Prasad ^a   Ganji, Dinesh ^a   Bedada, Sathish Kumar ^a  

^a KAKATIYA UNIVERSITY   (India)

Author keywords

Oral absorption; P glycoprotein; Permeability; Phenytoin; Single pass intestinal perfusion technique; Verapamil

Indexed keywords

GLYCOPROTEIN P; PHENYTOIN; PROPRANOLOL; VERAPAMIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; BLOOD SAMPLING; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; ILEUM; IN VIVO STUDY; INTESTINE PERFUSION; KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTICONVULSANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ILEUM; INTESTINAL ABSORPTION; MALE; P-GLYCOPROTEIN; PERFUSION; PERMEABILITY; PHENYTOIN; PROPRANOLOL; RATS; RATS, WISTAR; VERAPAMIL;

EID: 80052032792     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.05.005     Document Type: Conference Paper

References (39)

1. H.B. Aaron, S.C. Donna, B. Mistry, and N.D. Eddington Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats Epilepsy Res. 34 1999 129 133 (Pubitemid 29155483)
2. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, and I. Pastan Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu. Rev. Pharmacol. Toxicol. 39 1999 361 398 (Pubitemid 29222564)
3. T. Bansal, G. Mishrab, M. Jaggib, R.K. Khara, and S. Talegaonkara Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats Eur. J. Pharm. Sci. 36 2009 580 590
4. B. Bauer, M.S. Anika, H.P. Anton, K. Toellner, D.S. Miller, and H. Potschka Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling Mol. Pharmacol. 73 2008 1444 1453 (Pubitemid 351574834)
5. L. Candussio, G. Decorti, E. Crivellato, M. Granzotto, A. Rosati, T. Giraldi, and F. Bartoli Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin Life Sci. 71 2002 3109 3119 (Pubitemid 35284357)
6. L.T. Carlos, M. Fedrowitz, and L. Wolfgang Several major antiepileptic drugs are substrates for human P-glycoprotein Neuropharmacology 55 2008 1364 1375
7. W.L. Chiou, and A. Barve Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats Pharm. Res. 15 1998 1792 1795 (Pubitemid 28524594)
8. W. Chi-Yuan, and Z.B. Leslie Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm. Res. 22 2005 11 22
9. J.S. Choi, and X. Li The effect of verapamil on the pharmacokinetics of paclitaxel in rats Eur. J. Pharm. Sci. 24 2005 95 100 (Pubitemid 40051291)
10. J.M. Christopher, W.L. Matthew, L.R.B. Kim, and M.P. Gary Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation Pharmacotherapy 21 7 2001 778 796
11. A.H. Dantzig, D.P. de Alwis, and M. Burgess Considerations in the design and development of transport inhibitors as adjuncts to drug therapy Adv. Drug Deliv. Rev. 55 2003 133 150 (Pubitemid 36078455)
12. S. Deferme, P. Annaert, and P. Augustijns In vitro screening models to assess intestinal drug absorption and metabolism C. Ehrhardt, K.J. Kim, In Biotechnology - Pharmaceutical Aspects: Drug Absorption Studies 2008 Springer New York, NY 182 215
13. B. Griffin, and C. O'Driscoll Models of the Small Intestine C. Ehrhardt, K.J. Kim, In Biotechnology -Pharmaceutical Aspects: Drug Absorption Studies 2008 Springer New York, NY 34 76
14. P. Iannetti, A. Spalice, and P. Parisi Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus Epilepsia 46 2005 967 969 (Pubitemid 40847369)
15. E.J. Jeong, Y. Liu, H. Lin, and M. Hu In situ single-pass perfused rat intestinal model for absorption and metabolism Z. Yan, G.W. Caldwell, In Methods in Pharmacology and Toxicology: Optimization in Drug Discovery - In Vitro Methods 2004 Humana Totowa, NJ 65 76
16. P. Kishore, K. Rajnarayana, M.S. Reddy, J.V. Sagar, and D.R. Krishna Validated high performance liquid chromatographic method for simultaneous determination of phenytoin, phenobarbital and carbamazepine in human serum Arzneimittelforschung 53 11 2003 763 768 (Pubitemid 37463920)
17. C.M. Kruijtzer, J.H. Beijnen, H. Rosing, W.W. ten Bokkel Huinink, M. Schot, R.C. Jewell, E.M. Paul, and J.H. Schellens Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918 J. Clin. Oncol. 20 2002 2943 2950 (Pubitemid 34728888)
18. Y. Lu, Y. Yan, and X.F. Wang Antiepileptic drug-induced multidrug resistance P-glycoprotein overexpression in astrocytes cultured from rat brains Chin. Med. J. (Engl.) 117 2004 1682 1686 (Pubitemid 39619246)
19. D.S. Miller, B. Bauer, and A.M.S. Hartz Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve CNS pharmacotherapy Pharmacol. Rev. 60 2008 196 209 (Pubitemid 351962009)
20. R. Perez-Tomas Multidrug resistance: retrospect and prospects in anti-cancer drug treatment Curr. Med. Chem. 13 2006 1859 1876
21. V.B. Praveen, C. Saeho, and A.M. Richard Current methodologies used for evaluation of intestinal permeability and absorption J. Pharmacol. Toxicol. Methods 44 1 2000 301 312
22. M. Rizzi, S. Caccia, G. Guiso, C. Richichi, J.A. Gorter, E. Aronica, M. Aliprandi, R. Bagnati, R. Fanelli, M. D'Incalci, R. Samanin, and A. Vezzani Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance J. Neurosci. 22 2002 5833 5839
23. R.W. Robey, A. Lazarowski, and S.E. Bates P-glycoprotein - a clinical target in drug refractory epilepsy? Mol. Pharmacol. 73 2008 1343 1346 (Pubitemid 351574823)
24. L. Salphati, K. Childers, L. Pan, K. Tsutsui, and L. Takahashi Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man J. Pharm. Pharmacol. 53 2001 1007 1013 (Pubitemid 32640284)
25. N.N. Song, Q.S. Li, and C.X. Liu Intestinal permeability of Metformin using single-pass Intestinal perfusion in rats World J. Gastroenterol. 12 2006 4064 4070
26. R.H. Stephens, C.A. O'Neill, A. Warhurst, G.L. Carlson, M. Rowland, and G. Warhurst Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia J. Pharmacol. Exp. Ther. 296 2001 584 591 (Pubitemid 32112489)
27. M.A. Summers, J.L. Moore, and J.W. McAuley Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy Ann. Pharmacother. 38 2004 1631 1634 (Pubitemid 39297759)
28. S.C. Sutton, M.T. Rinaldi, and K.E. Vukovinsky Comparison of the gravimetric, phenol red, and 14c-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion model AAPS PharmSci. 25 2001 1 5
29. K. Takara, N. Ohnishi, S. Horibe, and T. Yokoyama Expression profiles of drugmetabolizing enzyme cyp3a and drug efflux transporter multidrug resistance 1 subfamily mRNAs in rat small intestine Drug Metab. Dispos. 31 2003 1235 1239 (Pubitemid 37152974)
30. E.A. Van Vliet, S. Redeker, E. Aronica, P.M. Edelbroek, and J.A. Gorter Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats Epilepsia 46 10 2005 1569 1580 (Pubitemid 44921930)
31. E.A. Van Vliet, R. van Schaik, P.M. Edelbroek, S. Redeker, E. Aronica, W.J. Wadman, N. Marchi, A. Vezzani, and J.A. Gorter Inhibition of the multidrug transporter Pglycoprotein improves seizure control in phenytoin-treated chronic epileptic rats Epilepsia 47 2006 672 680
32. E.A. Van Vliet, R. van Schaik, P.M. Edelbroek, R.A. Voskuyl, S. Redeker, E. Aronica, W.J. Wadman, and J.A. Gorter Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats J. Pharmacol. Exp. Ther. 322 2007 141 147 (Pubitemid 46956371)
33. M.V.S. Varma, and R. Panchagnula Enhanced oral paclitaxel absorption with vitamin ETPGS: effect on solubility and permeability in vitro, in situ and in vivo Eur. J. Pharm. Sci. 25 2005 445 453 (Pubitemid 40853872)
34. M.V.S. Varma, and R. Panchagnula Prediction of In vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability J. Pharm. Sci. 94 2005 1694 1704 (Pubitemid 41360864)
35. M.V.S. Varma, Y. Ashokraj, C.S. Dey, and R. Panchagnula P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement Pharmacol. Res. 48 2003 347 359 (Pubitemid 36945333)
36. M.V.S. Varma, K. Sateesh, and R. Panchagnula Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport Mol. Pharm. 2 1 2005 12 21 (Pubitemid 40314725)
37. J. Weiss, C.J. Kerpen, H. Lindenmaier, S.M. Dormann, and W.E. Haefeli Interaction of antiepileptic drugs with human P-glycoprotein in vitro J. Pharmacol. Exp. Ther. 307 2003 262 267 (Pubitemid 37151916)
38. M. Yamazaki, W.E. Neway, T. Ohe, I. Chen, J.F. Rowe, J.H. Hochman, M. Chiba, and J.H. Lin In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results J. Pharmacol. Exp. Ther. 296 2001 723 735 (Pubitemid 32187340)
39. P. Zakeri-Milani, H. Valizadeh, H. Tajerzadeh, Y. Azarmi, Z. Islambolchilar, S. Barzegar, and M. Barzegar-Jalali Predicting human intestinal permeability using single-pass intestinal perfusion in rat J. Pharm. Pharmaceut. Sci. 10 2007 368 379 (Pubitemid 350065177)